Bon Secours Health System

bonsecours.com

Bon Secours Health System, Inc. based in Marriottsville, Maryland, is a $3.2 billion dollar not-for-profit Catholic health system that owns, manages or joint ventures 18 acute care, 5 long term care, 4 assisted living, 6 retirement communities/senior housing, 14 home care and hospice services, and other facilities, primarily on the East Coast. Bon Secours Health System consists of more than 24,000 caregivers helping people in seven states. Its vision is to be a prophetic Catholic health ministry partnering with communities to create a more humane world, build health and social justice and provide exceptional value for those served.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

IONIS AND ASTRAZENECA CLOSE DEAL TO DEVELOP AND COMMERCIALIZE EPLONTERSEN

Ionis Pharmaceuticals, Inc. | December 30, 2021

news image

Ionis Pharmaceuticals, Inc. the leader in RNA-targeted therapies, announced the closing of the collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis' investigational antisense medicine for the treatment of transthyretin amyloidosis, following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Eplontersen, formerly known as IONIS-TTR-LRx, is designed to reduce the production of transthy...

Read More

Pharmacy Market

IQVIA AND NRX PHARMACEUTICALS COLLABORATE ON POTENTIAL MEDICAL SUPPORT FOR NOVEL COVID-19 TREATMENT

IQVIA™ | September 14, 2021

news image

IQVIA™ , a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a transformative collaboration with NRx Pharmaceuticals (NRx). NRx is a company dedicated to creating innovative, life-saving treatments and bringing hope to those facing life-altering conditions with no approved disease-modifying therapies or cures. IQVIA is excited to collaborate with NRx as its designated partner, to provide pharmac...

Read More

CPD AND LEARNING, VIEWS AND ANALYSIS

POSITIVE PHASE 2B TRIAL DATA: ZANIDATAMAB IN HER2-AMPLIFIED BILIARY TRACT CANCERS PRESENTED AT ASCO 2023 BY JAZZ PHARMACEUTICALS AND ZYMEWORKS

prnewswire | June 05, 2023

news image

Jazz Pharmaceuticals plc and Zymeworks Inc. (Nasdaq: ZYME) today presented positive pivotal trial data, including new data on progression-free survival (PFS), from the Phase 2b HERIZON-BTC-01 trial of the bispecific antibody zanidatamab in previously treated HER2-amplified biliary tract cancers (BTC). The data were featured as an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in The Lancet Oncology. The abst...

Read More

Research

MODERNA AND MEDISON PHARMA COLLABORATE TO COMMERCIALIZE MODERNA'S COVID-19 VACCINE IN CENTRAL EASTERN EUROPE AND ISRAEL

Moderna | June 08, 2021

news image

Moderna, Inc., a biotechnology company that pioneered messenger RNA (mRNA) therapeutics and vaccines, and Medison Pharma, a leading commercial partner for highly innovative therapies in international markets, announced today a new agreement to commercialize the Moderna COVID-19 Vaccine in Central Eastern Europe and Israel. Poland, Czech Republic, Romania, Hungary, Bulgaria, Slovenia, Slovakia, Croatia, Estonia, Latvia, Lithuania, Serbia, Ukraine, Moldova, Albania, Bosnia, and Herz...

Read More
news image

Pharmacy Market

IONIS AND ASTRAZENECA CLOSE DEAL TO DEVELOP AND COMMERCIALIZE EPLONTERSEN

Ionis Pharmaceuticals, Inc. | December 30, 2021

Ionis Pharmaceuticals, Inc. the leader in RNA-targeted therapies, announced the closing of the collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis' investigational antisense medicine for the treatment of transthyretin amyloidosis, following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Eplontersen, formerly known as IONIS-TTR-LRx, is designed to reduce the production of transthy...

Read More
news image

Pharmacy Market

IQVIA AND NRX PHARMACEUTICALS COLLABORATE ON POTENTIAL MEDICAL SUPPORT FOR NOVEL COVID-19 TREATMENT

IQVIA™ | September 14, 2021

IQVIA™ , a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a transformative collaboration with NRx Pharmaceuticals (NRx). NRx is a company dedicated to creating innovative, life-saving treatments and bringing hope to those facing life-altering conditions with no approved disease-modifying therapies or cures. IQVIA is excited to collaborate with NRx as its designated partner, to provide pharmac...

Read More
news image

CPD AND LEARNING, VIEWS AND ANALYSIS

POSITIVE PHASE 2B TRIAL DATA: ZANIDATAMAB IN HER2-AMPLIFIED BILIARY TRACT CANCERS PRESENTED AT ASCO 2023 BY JAZZ PHARMACEUTICALS AND ZYMEWORKS

prnewswire | June 05, 2023

Jazz Pharmaceuticals plc and Zymeworks Inc. (Nasdaq: ZYME) today presented positive pivotal trial data, including new data on progression-free survival (PFS), from the Phase 2b HERIZON-BTC-01 trial of the bispecific antibody zanidatamab in previously treated HER2-amplified biliary tract cancers (BTC). The data were featured as an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in The Lancet Oncology. The abst...

Read More
news image

Research

MODERNA AND MEDISON PHARMA COLLABORATE TO COMMERCIALIZE MODERNA'S COVID-19 VACCINE IN CENTRAL EASTERN EUROPE AND ISRAEL

Moderna | June 08, 2021

Moderna, Inc., a biotechnology company that pioneered messenger RNA (mRNA) therapeutics and vaccines, and Medison Pharma, a leading commercial partner for highly innovative therapies in international markets, announced today a new agreement to commercialize the Moderna COVID-19 Vaccine in Central Eastern Europe and Israel. Poland, Czech Republic, Romania, Hungary, Bulgaria, Slovenia, Slovakia, Croatia, Estonia, Latvia, Lithuania, Serbia, Ukraine, Moldova, Albania, Bosnia, and Herz...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us